[ad_1]
The efficacy of the two-dose vaccine based on the ribonucleic acid (mRNA) reporting method is 95%. Its distribution has been approved by the World Health Organization (WHO) and around 50 other countries.
However, their supply is limited, and countries around the world aim to vaccinate their populations as soon as possible against the coronavirus, which has carried 2.2 million people for a year. lives.
A report from Novartis says that Pfizer-BioNTech will be assisted in vaccine production by its sterile production lines in Stein, Switzerland.
VIDEO: I.Šimonytė: the extension of the quarantine does not mean that this regime will be valid for a whole month
Under the agreement, Novartis will take “the active ingredient from BioNTech’s mRNA, bottle it under sterile conditions, and then return BioNTech for further distribution to healthcare customers around the world,” according to the report.
Following the final agreement, Novartis expects to begin work in the second quarter of this year and ship the final product in the third quarter.
Steffen Lang, Novartis head of technical operations, noted that the company is committed to “adapting our production capacity to contribute to the supply and therapy of COVID-19 vaccines worldwide.”
“We hope it will be the first in a series of agreements of this type,” he said in a statement.
Novartis has reported progress in negotiations with a chain of other companies for assistance in its vaccine manufacturing process, including the production of mRNA, therapeutic proteins and raw materials for COVID-19 vaccines.
[ad_2]
